Q1
MCK — Q1 2026 Financial Report Analysis
McKesson's fiscal Q1 2027 (Apr–Jun 2026) revenue rose 8% to $105.4B and adjusted EPS 20% to $9.93 on specialty-drug volume, but GAAP EPS fell 18% to $5.15 on a $293M non-cash charge tied to Apollo's Med-Surg stake; FY27 guidance raised to $44.20–$45.00.